Literature DB >> 21084997

Risk factors influencing antibody responses to Kaposi's sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy.

Moraima Guadalupe1, Brad H Pollock, Steven Westbrook, Spencer Redding, Delia Bullock, Gregory Anstead, Brian K Agan, Vincent C Marconi, Sharon Barbieri, Vidya Sankar, Jennifer Rebeles, Yvette Flahive, John Schoolfield, Linding Wang, Xiufen Lei, Dorothy Dow, Chih-Ko Yeh, Howard Dang, Anthony J Infante, Shou-Jiang Gao.   

Abstract

BACKGROUND: Kaposi's sarcoma-associated herpesvirus (KSHV) seropositivity and lytic antibody titer are predictors for Kaposi's sarcoma.
METHODS: We examined demographic, viral, and immunologic factors that influence KSHV latent and lytic antibodies in HIV-infected patients.
RESULTS: Detection rate of KSHV latent but not lytic antibodies was lower in patients with CD4 cells/mm3 less than 200 than greater than 200 (odds ratio [OR], 0.26; 95% confidence interval [CI], 0.11-0.61) and CD8 cells/mm3 less than 400 than greater than 400 (OR, 0.26; 95% CI, 0.07-0.67). Overall seropositivity rate was higher in patients with CD4 cells/mm3 less than 200 than greater than 200 (OR, 2.34; 95% CI, 1.37-4.02) and HIV copies/mL greater than 400 than less than 400 (OR, 1.70; 95% CI, 1.09-2.65). Lytic antibody level was inversely correlated with CD4 count (P < 0.001). Lytic seropositivity (OR, 2.47; 95% CI, 1.35-4.50) and antibody level (adjusted difference mean optical density, 0.324; 95% CI, 0.16-0.46) were higher in patients with HIV infection greater than 15 than less than 15 years. Hispanics had higher lytic seropositivity rate (OR, 1.71; 95% CI, 1.07-2.73) and antibody level (adjusted difference mean optical density, 0.111; 95% CI, 0.03-0.18) than non-Hispanics.
CONCLUSIONS: Lower CD4 and CD8 counts impair antibody response to KSHV latent antigens. Immune deterioration, long-term HIV infection, and Hispanic status are risk factors for Kaposi's sarcoma predictors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21084997      PMCID: PMC3051282          DOI: 10.1097/QAI.0b013e3181fdc928

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  41 in total

1.  Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. Adult/Adolescent Spectrum of HIV Disease Project Group.

Authors:  J L Jones; D L Hanson; M S Dworkin; J W Ward; H W Jaffe
Journal:  J Acquir Immune Defic Syndr       Date:  1999-08-01       Impact factor: 3.731

2.  Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group.

Authors:  D F Martin; B D Kuppermann; R A Wolitz; A G Palestine; H Li; C A Robinson
Journal:  N Engl J Med       Date:  1999-04-08       Impact factor: 91.245

3.  Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.

Authors:  C Lebbé; L Blum; C Pellet; G Blanchard; O Vérola; P Morel; O Danne; F Calvo
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

4.  Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen.

Authors:  G R Simpson; T F Schulz; D Whitby; P M Cook; C Boshoff; L Rainbow; M R Howard; S J Gao; R A Bohenzky; P Simmonds; C Lee; A de Ruiter; A Hatzakis; R S Tedder; I V Weller; R A Weiss; P S Moore
Journal:  Lancet       Date:  1996-10-26       Impact factor: 79.321

5.  KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma.

Authors:  S J Gao; L Kingsley; M Li; W Zheng; C Parravicini; J Ziegler; R Newton; C R Rinaldo; A Saah; J Phair; R Detels; Y Chang; P S Moore
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

6.  Evidence for concurrent epidemics of human herpesvirus 8 and human immunodeficiency virus type 1 in US homosexual men: rates, risk factors, and relationship to Kaposi's sarcoma.

Authors:  T R O'Brien; D Kedes; D Ganem; D R Macrae; P S Rosenberg; J Molden; J J Goedert
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

7.  Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy.

Authors:  Anna Maria Cattelan; Maria Luisa Calabrò; Anita De Rossi; Savina Maria Luciana Aversa; Massimo Barbierato; Marco Trevenzoli; Paola Gasperini; Marisa Zanchetta; Paolo Cadrobbi; Silvio Monfardini; Luigi Chieco-Bianchi
Journal:  Int J Oncol       Date:  2005-09       Impact factor: 5.650

8.  Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma.

Authors:  P S Moore; L A Kingsley; S D Holmberg; T Spira; P Gupta; D R Hoover; J P Parry; L J Conley; H W Jaffe; Y Chang
Journal:  AIDS       Date:  1996-02       Impact factor: 4.177

9.  Interassay correlation of human herpesvirus 8 serologic tests. HHV-8 Interlaboratory Collaborative Group.

Authors:  C S Rabkin; T F Schulz; D Whitby; E T Lennette; L I Magpantay; L Chatlynne; R J Biggar
Journal:  J Infect Dis       Date:  1998-08       Impact factor: 5.226

10.  A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in adults with human immunodeficiency virus-1.

Authors:  R Newton; L Carpenter; D Casabonne; V Beral; A Babiker; J Darbyshire; I Weller; R Weiss; A Kwan; D Bourboulia; F Munoz; D Lagos; C Boshoff
Journal:  Br J Cancer       Date:  2006-05-22       Impact factor: 7.640

View more
  14 in total

1.  Kaposi's sarcoma: a 10-year experience with 248 patients at a single tertiary care hospital in Tanzania.

Authors:  Phillipo L Chalya; Fidelis Mbunda; Peter F Rambau; Hyasinta Jaka; Nestory Masalu; Mariam Mirambo; Martha F Mushi; Samuel E Kalluvya
Journal:  BMC Res Notes       Date:  2015-09-15

2.  FoxO1 Suppresses Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication and Controls Viral Latency.

Authors:  Ruoyun Gao; Tingting Li; Brandon Tan; Suzane Ramos da Silva; Jae U Jung; Pinghui Feng; Shou-Jiang Gao
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

3.  High seroprevalence of antibodies against Kaposi's sarcoma-associated herpesvirus (KSHV) among HIV-1-infected children and adolescents in a non-endemic population.

Authors:  Cornelia Feiterna-Sperling; Christoph Königs; Gundula Notheis; Bernd Buchholz; Renate Krüger; Katharina Weizsäcker; Josef Eberle; Nikola Hanhoff; Barbara Gärtner; Harald Heider; Detlev H Krüger; Jörg Hofmann
Journal:  Med Microbiol Immunol       Date:  2016-05-30       Impact factor: 3.402

4.  Activation of Kaposi's sarcoma-associated herpesvirus (KSHV) by inhibitors of class III histone deacetylases: identification of sirtuin 1 as a regulator of the KSHV life cycle.

Authors:  Qiuhua Li; Meilan He; Fuchun Zhou; Fengchun Ye; Shou-Jiang Gao
Journal:  J Virol       Date:  2014-03-26       Impact factor: 5.103

5.  Screening of the Human Kinome Identifies MSK1/2-CREB1 as an Essential Pathway Mediating Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication during Primary Infection.

Authors:  Fan Cheng; Tanvee Vinod Sawant; Ke Lan; Chun Lu; Jae U Jung; Shou-Jiang Gao
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

6.  Antibody responses to lytic and latent human herpesvirus 8 antigens among HIV-infected patients in central China.

Authors:  T J Zhang; N He; Y Y Ding; Q W Jiang; C Wood
Journal:  Biosci Trends       Date:  2012-06       Impact factor: 2.400

7.  TLR4-Mediated Inflammation Promotes KSHV-Induced Cellular Transformation and Tumorigenesis by Activating the STAT3 Pathway.

Authors:  Marion Gruffaz; Karthik Vasan; Brandon Tan; Suzane Ramos da Silva; Shou-Jiang Gao
Journal:  Cancer Res       Date:  2017-10-19       Impact factor: 12.701

8.  Mechanisms of Kaposi's Sarcoma-Associated Herpesvirus Latency and Reactivation.

Authors:  Fengchun Ye; Xiufen Lei; Shou-Jiang Gao
Journal:  Adv Virol       Date:  2011

9.  Nitric oxide is induced and required for efficient Kaposi's sarcoma-associated herpesvirus lytic replication.

Authors:  Antonia Herrera-Ortíz; Wen Meng; Shou-Jiang Gao
Journal:  J Med Virol       Date:  2021-07-29       Impact factor: 2.327

10.  Trends in Kaposi's Sarcoma in Miami Beach from 1987 to 2007.

Authors:  Simon B Zeichner; Ana L Ruiz; Gabriel P Suciu; Rachel Lerner Zeichner; Estelamari Rodriguez
Journal:  ISRN Oncol       Date:  2012-12-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.